Latest Review,1

Glucagon-like peptide-1 (GLP-1), and its receptor agonists, have emerged as significant therapeutic agents in the management of metabolic diseases, particularly type 2 diabetes and obesity. This article delves into the multifaceted role of GLP-1 and its derivatives, offering an in-depth look at their mechanisms, applications, and emerging potential.

The Physiology of GLP-1

Glucagon-like peptide-1 is an incretin hormone naturally produced in the gut enteroendocrine cells in response to nutrient intake. Its primary function is to regulate glucose homeostasis. Unlike GIP (glucose-dependent insulinotropic polypeptide), the action of GLP-1 is preserved in patients with type 2 diabetes. GLP-1 acts as an incretin, promoting glucose-stimulated insulin release. It also increases both proinsulin gene transcription and mRNA stability, leading to an enhanced insulin response. Furthermore, GLP-1 released from gut enteroendocrine cells controls meal-related glycemic excursions through augmentation of insulin secretion and inhibition of glucagon secretion. Decreased secretion of GLP-1 may contribute to the development of obesity, and exaggerated secretion may be responsible for postprandial reactive hypoglycemia.

GLP-1 Receptor Agonists: A Therapeutic Revolution

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications that mimic the action of natural GLP-1, thereby enhancing its beneficial effects on blood sugar regulation. These drugs are also known as GLP-1 analogues or GLP-1 RAs.

Key Applications and Benefits of GLP-1 Receptor Agonists:

* Type 2 Diabetes Management: GLP-1 agonists are a cornerstone in managing type 2 diabetes mellitus (T2DM). They improve glycemic control by enhancing insulin secretion and suppressing glucagon release. Studies indicate that GLP-1 agonists effectively reverse the trend of weight gain and improve A1C levels in patients with type 2 diabetes. For individuals with type 2 diabetes, GLP-1 agonists are a type of medication that may be necessary. They help lower blood sugar and slow digestion. Furthermore, GLP-1 medicines reduce the risk of MACE (major adverse cardiovascular events) and cardiovascular death in people with type 2 diabetes or obesity. GLP-1 receptor agonists improve glycemic control in patients with type 2 diabetes mellitus, have cardioprotective and renoprotective effects, and do not cause weight gain. The combination of (basal) insulin with a GLP-1RA is a highly effective treatment even for advanced stages of type 2 diabetes. GLP-1 agonist therapy can delay insulin initiation or reduce insulin doses. GLP-1 is effective in patients with type 2 diabetes, increasing insulin secretion and normalizing both fasting and postprandial blood glucose when given as a therapeutic.

* Obesity Treatment: Beyond diabetes, GLP-1 agonists have shown remarkable efficacy in weight management. GLP-1 drugs for weight loss are increasingly popular. Glucagon-like peptide-1 receptor agonists are now frequently used by type 1 diabetes patients, despite limited data on the drugs' long-term effects.

* Emerging Role in Type 1 Diabetes: While initially developed for type 2 diabetes, there is growing evidence suggesting that GLP-1 receptor agonists may also benefit individuals with type 1 diabetes. Research indicates that GLP-1 RAs may be beneficial against major adverse cardiorenal events in patients with type 1 diabetes. Some studies suggest that GLP-1 agonists could significantly change the management of type 1 diabetes by β-cell preservation and improving glycemic parameters with lower insulin doses. There is real-world evidence of GLP-1 receptor agonists improving the lives of people with type 1 diabetes. The GLP-1 RAs in the management of T1D are an area of active investigation. Explaining why people with type 1 diabetes have lower circulating GLP-1 concentrations is difficult, and efforts are being made to understand this phenomenon.

* Cardiovascular and Renal Benefits: A significant advantage of GLP-1 receptor agonists is their demonstrated cardiovascular and renal protective effects. These benefits extend beyond glucose control, reducing the risk of major adverse cardiovascular events and improving kidney function.

* Metabolic Diseases: GLP-1 plays a key role in the occurrence and development of metabolic diseases such as obesity, nonalcoholic fatty liver disease, and other related conditions.

Specific GLP-1 Based Therapies:

Several GLP-1 based therapies are available, including well-known medications such as semaglutide and tirzepatide. A synthetic dual-acting GIP and GLP-1 receptor agonist (tirzepatide) is available for the treatment of